Lack of Clinically Relevant Drug-Drug Interaction Between Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Verapamil, Ramipril, or Digoxin in Healthy Volunteers

Clinical Therapeutics

Volumn 35, Issue 3, 2013, Pages 226-235

  Macha, Sreeraj ^a   Sennewald, Regina ^b   Rose, Peter ^b   Schoene, Katja ^b   Pinnetti, Sabine ^b   Woerle, Hans J ^b   Broedl, Uli C ^b  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Digoxin; Drug drug interaction; Empagliflozin; Ramipril; SGLT2 inhibitor; Type 2 diabetes; Verapamil

Indexed keywords

DIGOXIN; EMPAGLIFLOZIN; RAMIPRIL; RAMIPRILAT; VERAPAMIL;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CROSSOVER PROCEDURE; DIZZINESS; DRUG INTERACTION; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; HYPERVENTILATION; INFLUENZA; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; CROSS-OVER STUDIES; DIGOXIN; DRUG INTERACTIONS; FEMALE; GLUCOSIDES; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; RAMIPRIL; REFERENCE VALUES; SODIUM-GLUCOSE TRANSPORTER 2; VERAPAMIL; YOUNG ADULT;

EID: 84874966394     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.02.015     Document Type: Article

References (33)

1. Danaei G., Finucane M.M., Lu Y., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378:31-40.
2. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
3. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
4. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
5. Mather A., Pollock C. Glucose handling by the kidney. Kidney Int Suppl 2011, S1-S6.
6. Rahmoune H., Thompson P.W., Ward J.M., et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005, 54:3427-3434.
7. DeFronzo R.A., Davidson J.A., Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012, 14:5-14.
8. Grempler R., Thomas L., Eckhardt M., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012, 14:83-90.
9. Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT-2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Develop. In press.
10. Heise T., Seewaldt-Becker E., Macha S., et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013 Jan 28, [Epub ahead of print].
11. Seman L., Macha S., Jones P., et al. Safety and tolerability of BI 10773, a sodium-glucose co-transporter (SGLT-2) inhibitor, following 8-days treatment in patients with type 2 diabetes. Diabetes 2010, 59:A156. [571-P].
12. Ferrannini E., Seman L., Seewaldt-Becker E., et al. A phase IIb, randomised, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013 Feb 8, [Epub ahead of print].
13. Rosenstock J., Jelaska A., Seman L., et al. Efficacy and safety of BI 10773, a new sodium glucose cotransporter (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin. Diabetes 2011, 60(Suppl 1):A271. [989-P].
14. Preis S.R., Hwang S.J., Coady S., et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119:1728-1735.
15. Preis S.R., Pencina M.J., Hwang S.J., et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation 2009, 120:212-220.
16. Sarwar N., Gao P., Seshasai S.R., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
17. Tzoulaki I., Molokhia M., Curcin V., et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009, 339:b4731.
18. Whalen K.L., Stewart R.D. Pharmacologic management of hypertension in patients with diabetes. Am Fam Physician 2008, 78:1277-1282.
19. Huxley R.R., Alonso A., Lopez F.L., et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart 2012, 98:133-138.
20. Nichols G.A., Reinier K., Chugh S.S. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care 2009, 32:1851-1856.
21. Nichols G.A., Hillier T.A., Erbey J.R., Brown J.B. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001, 24:1614-1619.
22. Zhou L., Deng W., Zhou L., et al. Prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population: systematic review. Curr Diabetes Rev 2009, 5:171-184.
23. Béjot Y., Giroud M. Stroke in diabetic patients. Diabetes Metab 2010, (Suppl 3):S84-S87.
24. Verapamil hydrochoride [prescribing information] 2011, Watson Pharmaceuticals, Accessed May 14, 2012. http://pi.watson.com/data_stream.asp?product_group=1323&p=pi&language=E.
25. Lemma G.L., Wang Z., Hamman M.A., et al. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 2006, 79:218-230.
26. Tracy T.S., Korzekwa K.R., Gonzalez F.J., Wainer I.W. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 1999, 47:545-552.
27. Kroemer H.K., Gautier J.C., Beaune P., et al. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1993, 348:332-337.
28. Eichelbaum M., Ende M., Remberg G., et al. The metabolism of DL-[14C]verapamil in man. Drug Metab Dispos 1979, 7:145-148.
29. Ramipril [prescribing information] 2011, US Food and Drug Administration, Accessed March 26, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019901s058lbl.pdf.
30. Digoxin [prescribing information] 2002, US Food and Drug Administration, Accessed May 14, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/76268_Digoxin_Prntlbl.pdf.
31. Tanigawara Y., Okamura N., Hirai M., et al. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 1992, 263:840-845.
32. Rautio J., Humphreys J.E., Webster L.O., et al. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 2006, 34:786-792.
33. Ding R., Tayrouz Y., Riedel K.D., et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004, 76:73-84.